The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     
 

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Liu, Z.
Right arrow Articles by Suciu-Foca, N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Liu, Z.
Right arrow Articles by Suciu-Foca, N.

The Journal of Immunology, Vol 150, Issue 8 3180-3186, Copyright © 1993 by American Association of Immunologists

ARTICLES

Limited usage of T cell receptor V beta genes by allopeptide-specific T cells

Z Liu, YK Sun, YP Xi, B Hong, PE Harris, EF Reed and N Suciu-Foca
College of Physicians & Surgeons of Columbia University, Department of Pathology, New York, NY 10032.

T cell reactivity to alloantigens results from direct and indirect recognition of allogeneic MHC molecules and/or peptides. Although direct recognition is not self-MHC restricted, indirect recognition, the result of alloantigen processing and presentation by host APC, is restricted by the self (responder) MHC molecule to which the allopeptide has bound. We have studied the MHC restriction and TCR usage in T cell alloreactivity to a synthetic peptide corresponding to amino acid residues 21-42 of the DR beta 1*0101 molecule. T cell lines were developed by in vitro immunization of T cells from three responders carrying the DR beta 1*1101 allele with this peptide. In all three responders, reactivity to peptide 21-42 was restricted by the DR11 molecule. A limited usage of V beta genes was found in these T cell lines, all of which shared the expression of V beta 13.2. Because indirect recognition of allopeptide may play an important role in chronic, antibody-mediated allograft rejection, study of the TCR gene usage may contribute to the development of specific immunosuppression therapy.


This article has been cited by other articles:


Home page
 J. Immunol.Home page
E. V. Fedoseyeva, K. Kishimoto, H. K. Rolls, B. M.-W. Illigens, V. M. Dong, A. Valujskikh, P. S. Heeger, M. H. Sayegh, and G. Benichou
Modulation of Tissue-Specific Immune Response to Cardiac Myosin Can Prolong Survival of Allogeneic Heart Transplants
J. Immunol., August 1, 2002; 169(3): 1168 - 1174.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
C. A. Slachta, V. Jeevanandam, B. Goldman, W. L. Lin, and C. D. Platsoucas
Coronary Arteries from Human Cardiac Allografts with Chronic Rejection Contain Oligoclonal T Cells: Persistence of Identical Clonally Expanded TCR Transcripts from the Early Post-Transplantation Period (Endomyocardial Biopsies) to Chronic Rejection (Coronary Arteries)
J. Immunol., September 15, 2000; 165(6): 3469 - 3483.
[Abstract] [Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
B. MURPHY and A. M. KRENSKY
HLA-Derived Peptides as Novel Immunomodulatory Therapeutics
J. Am. Soc. Nephrol., June 1, 1999; 10(6): 1346 - 1355.
[Abstract] [Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Website Copyright © 1993 by The American Association of Immunologists, Inc. All rights reserved.
All Contents Copyright © 1993 by The American Association of Immunologists, Inc. All rights reserved.